Metraipolis › archive › dc_a0bb724fe109

Drug Repurposing for Inclusion of COVID-19-Related Indication: Field Study of the European Medicines Agency's Response to the Pandemic — Europe PMC PMID:41441327

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41441327
DOI
10.3390/pharmacy13060179
License (as archived)
solo-consultazione
Archived
2026-11-07T17:54:15.964Z
SHA-256 of the archived text
a0262e8b40354456192c5c0f0bfab082e10bdce9c94dca9eae1c4abf9dc2d087
Stable URL of this page
https://metraipolis.com/documento/dc_a0bb724fe109

How to cite

Drug Repurposing for Inclusion of COVID-19-Related Indication: Field Study of the European Medicines Agency's Response to the Pandemic — Europe PMC PMID:41441327 — Europe PMC (en), https://europepmc.org/article/MED/41441327 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a0bb724fe109 (Metraipolis archive dc_a0bb724fe109, sha256 a0262e8b40354456192c5c0f0bfab082e10bdce9c94dca9eae1c4abf9dc2d087)
BibTeX
@misc{dca0bb724fe109,
  title = {Drug Repurposing for Inclusion of COVID-19-Related Indication: Field Study of the European Medicines Agency's Response to the Pandemic — Europe PMC PMID:41441327},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41441327},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a0bb724fe109; sha256 a0262e8b40354456192c5c0f0bfab082e10bdce9c94dca9eae1c4abf9dc2d087},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41441327. Agents can read the archived copy with the MCP tool read_document.